JP2008237117A - Anti-fatigue food raw material and anti-fatigue food - Google Patents
Anti-fatigue food raw material and anti-fatigue food Download PDFInfo
- Publication number
- JP2008237117A JP2008237117A JP2007082940A JP2007082940A JP2008237117A JP 2008237117 A JP2008237117 A JP 2008237117A JP 2007082940 A JP2007082940 A JP 2007082940A JP 2007082940 A JP2007082940 A JP 2007082940A JP 2008237117 A JP2008237117 A JP 2008237117A
- Authority
- JP
- Japan
- Prior art keywords
- fatigue
- benzylglucosinolate
- group
- extract
- fatigue food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 93
- 230000002929 anti-fatigue Effects 0.000 title claims abstract description 84
- 239000002994 raw material Substances 0.000 title abstract 7
- QQGLQYQXUKHWPX-SUYBVFMFSA-N benzyl glucosinolate Natural products S(=O)(=O)(O/N=C(/S[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](CO)O1)\Cc1ccccc1)O QQGLQYQXUKHWPX-SUYBVFMFSA-N 0.000 claims abstract description 74
- QQGLQYQXUKHWPX-RFEZBLSLSA-N glucotropeolin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1S\C(=N/OS(O)(=O)=O)CC1=CC=CC=C1 QQGLQYQXUKHWPX-RFEZBLSLSA-N 0.000 claims abstract description 74
- 241000219193 Brassicaceae Species 0.000 claims abstract description 12
- 241000801118 Lepidium Species 0.000 claims abstract description 12
- 240000001260 Tropaeolum majus Species 0.000 claims abstract description 8
- 235000004424 Tropaeolum majus Nutrition 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims description 53
- 240000000759 Lepidium meyenii Species 0.000 claims description 41
- 235000000421 Lepidium meyenii Nutrition 0.000 claims description 41
- 235000012902 lepidium meyenii Nutrition 0.000 claims description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims 1
- 238000011084 recovery Methods 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 230000009182 swimming Effects 0.000 description 20
- 230000000694 effects Effects 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 230000003078 antioxidant effect Effects 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 241000219173 Carica Species 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 235000009467 Carica papaya Nutrition 0.000 description 9
- 238000011068 loading method Methods 0.000 description 7
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 241000339449 Moringa stenopetala Species 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 238000004020 luminiscence type Methods 0.000 description 5
- 238000000692 Student's t-test Methods 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- LXEKPEMOWBOYRF-QDBORUFSSA-N AAPH Chemical compound Cl.Cl.NC(=N)C(C)(C)\N=N\C(C)(C)C(N)=N LXEKPEMOWBOYRF-QDBORUFSSA-N 0.000 description 3
- 241000554155 Andes Species 0.000 description 3
- 240000003291 Armoracia rusticana Species 0.000 description 3
- 235000011330 Armoracia rusticana Nutrition 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002518 antifoaming agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- -1 lipid peroxides Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 238000011891 EIA kit Methods 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 244000179886 Moringa oleifera Species 0.000 description 2
- 235000011347 Moringa oleifera Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960002900 methylcellulose Drugs 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 102100040038 Amyloid beta precursor like protein 2 Human genes 0.000 description 1
- 235000014649 Carica monoica Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000890401 Homo sapiens Amyloid beta precursor like protein 2 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 235000017879 Nasturtium officinale Nutrition 0.000 description 1
- 240000005407 Nasturtium officinale Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 241000533293 Sesbania emerus Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 235000000760 Wasabia japonica Nutrition 0.000 description 1
- 244000195452 Wasabia japonica Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 0 [*-]N=C(Cc1ccccc1)S* Chemical compound [*-]N=C(Cc1ccccc1)S* 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 125000004383 glucosinolate group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、抗疲労食品素材並びに該食品素材を含有してなる抗疲労食品に関し、詳細には、少なくともベンジルグルコシノレートを含む抗疲労食品素材及び該食品素材を含有してなる抗疲労食品に関する。 TECHNICAL FIELD The present invention relates to an anti-fatigue food material and an anti-fatigue food containing the food material, and more particularly to an anti-fatigue food material containing at least benzylglucosinolate and an anti-fatigue food containing the food material. .
現在、「疲労」は大きな社会問題となっており、「過労死(Karoshi)」という言葉は、不名誉な日本発の国際語である。これは長時間過密の働きすぎによる突然死を指し、社会問題として大きくクローズアップされている。このように疲労の問題は社会的、経済的にも重要なものであるにもかかわらず、その対策はいまだ立ち遅れているのが現状である。 Currently, “fatigue” is a major social problem, and the word “Karoshi” is an unfamous international word for Japan. This refers to sudden death due to overcrowding for a long time, and is greatly highlighted as a social problem. Despite the fact that the problem of fatigue is socially and economically important, the countermeasures are still behind.
抗疲労食品に関して、例えば、特許文献1には、焙煎コーヒー豆の抽出物を含有し、経口摂取により精神的ストレスを緩和させる作用を有した飲食品が精神的ストレスの緩和のために用いられる旨が開示されている。特許文献2には、プロアントシアニジン、ブドウ種子、皮の抽出物又は赤ワインエキスを含む抗疲労ドリンク剤が開示されている。
Regarding anti-fatigue foods, for example,
これら特許文献が示すように、疲労に関する研究が徐々に進んでいる。しかしながら、現代社会には未だ疲労が蔓延しており、疲労回復に有効な抗疲労食品の創出が望まれているのが現状である。 As these patent documents show, research on fatigue is gradually progressing. However, fatigue is still widespread in the modern society, and the present situation is that creation of anti-fatigue foods effective for fatigue recovery is desired.
マカ(Lepidium. meyenii Walp.)は、アンデス山脈のアブラナ科(異名Cruciferae,)に属する作物である。レピディアム属は、およそ175種(Mummenhoffほか1992)から成り、南極大陸を除いて世界中全ての大陸に広く分布している。このマカは、現地では民間伝承薬として用いられ、貧血症、不妊症あるいは精力減退症などへの有効性が知られている。例えば、特許文献3には、マカを含有する血中成長ホルモン量上昇、持久力増加作用を有する機能性食品が開示されている。また、特許文献4には、マカを含有するテストステロン増加組成物が開示されている。
本発明は、上記問題に鑑みてなされたものであり、天然物由来成分を含む抗疲労食品素材及び抗疲労食品を提供することを課題とする。詳細には、マカ(Lepidium meyenii-Walp, Cruciferae)に含まれるベンジルグルコシノレートを有効成分として含む抗疲労食品素材並びに該食品素材を含有してなる抗疲労食品を提供することを課題とする。 This invention is made | formed in view of the said problem, and makes it a subject to provide the anti-fatigue food material and anti-fatigue food containing a natural product origin component. Specifically, it is an object to provide an anti-fatigue food material containing benzyl glucosinolate contained in maca (Lepidium meyenii-Walp, Cruciferae) as an active ingredient, and an anti-fatigue food containing the food material.
本発明者らは、天然物であるマカ(Lepidium meyenii-Walp, Cruciferae)に含まれるベンジルグルコシノレートが優れた抗疲労効果を示すことを見出し本発明に至った。 The present inventors have found that benzylglucosinolate contained in a natural product, maca (Lepidium meyenii-Walp, Cruciferae), exhibits an excellent anti-fatigue effect, leading to the present invention.
請求項1に係る発明は、下式(化1)で示されるベンジルグルコシノレートを含む抗疲労食品素材に関する。
The invention according to
請求項5に係る発明は、請求項1乃至4いずれかに記載の抗疲労食品素材を含有してなる抗疲労食品に関する。
請求項6に係る発明は、前記抗疲労食品素材が、ベンジルグルコシノレート含量0.00001〜10重量%となるように含有してなることを特徴とする請求項5記載の抗疲労食品に関する。
The invention according to claim 5 relates to an anti-fatigue food comprising the anti-fatigue food material according to any one of
The invention according to claim 6 relates to the anti-fatigue food according to claim 5, wherein the anti-fatigue food material is contained so as to have a benzylglucosinolate content of 0.00001 to 10% by weight.
本発明の抗疲労食品素材及び抗疲労食品は、有効成分としてベンジルグルコシノレートを含むから、優れた疲労回復効果を有する。詳細には、疲労が蓄積した被験物の脳内ホルモン分泌低下を抑制する。 Since the anti-fatigue food material and anti-fatigue food of the present invention contain benzyl glucosinolate as an active ingredient, they have an excellent fatigue recovery effect. Specifically, it suppresses a decrease in brain hormone secretion in a test subject in which fatigue has accumulated.
本発明の抗疲労食品素材及び抗疲労食品の他の有利な点は、その抗酸化効果によりストレスを軽減することができる。さらにその抗酸化効果により、活性酸素により引き起こされるような老化、皮膚のシワ形成等、或いは不飽和脂肪酸が体内で活性酸素によって酸化され生成される過酸化脂質により引き起こされ得る様々な症状を防ぐことができる。 Another advantage of the anti-fatigue food material and anti-fatigue food of the present invention is that it can reduce stress due to its antioxidant effect. In addition, its antioxidant effect prevents various symptoms that can be caused by aging, skin wrinkle formation, etc. caused by active oxygen, or lipid peroxides that are produced by oxidation of unsaturated fatty acids by active oxygen in the body. Can do.
本発明の抗疲労食品素材は、下式(化4)で示されるベンジルグルコシノレート(学名:Benzyl glucosinolate)を含む。 The anti-fatigue food material of the present invention includes benzyl glucosinolate (scientific name: Benzyl glucosinolate) represented by the following formula (Formula 4).
他の実施形態として、本発明の抗疲労食品素材は、マカ(Lepidium meyenii-Walp, Cruciferae)及び/又はナスタチウム(Tropaeolum majus)の抽出物及び/又は濃縮抽出物からなり、少なくとも上式(化4)で示されるベンジルグルコシノレートを含む。 In another embodiment, the anti-fatigue food material of the present invention comprises an extract and / or concentrated extract of maca (Lepidium meyenii-Walp, Cruciferae) and / or Nastathium (Tropaeolum majus), and at least the above formula (Formula 4). Benzyl glucosinolate shown in FIG.
本発明に係るマカ(Lepidium meyenii-Walp, Cruciferae)(以下、マカという)は、多年生草本で、ペルー等の中央アンデスの標高4000〜4500m程度の高山地で栽培されている根菜である。現地では民間伝承薬として用いられ、滋養強壮、栄養不良、貧血症、不妊症あるいは精力減退症などへの有効性が知られている。マカは、タンパク質、アミノ酸、ミネラル、ビタミン、必須脂肪酸等の成分を含んでいる。 Maca (Lepidium meyenii-Walp, Cruciferae) (hereinafter referred to as Maca) according to the present invention is a perennial herb and is a root vegetable grown in alpine areas of an altitude of about 4000 to 4500 m in the central Andes such as Peru. It is used locally as a folklore medicine and is known to be effective for nutritional tonicity, malnutrition, anemia, infertility, or energy loss. Maca contains ingredients such as proteins, amino acids, minerals, vitamins and essential fatty acids.
ナスタチウム(Tropaeolum majus)(以下、ナスタチウムという)は、春まき1年草として花壇や鉢植えに栽培される多年草で、原種はつる性で長さ1〜2mにのび、葉はハスの葉に似た楯状である。その原産地は、ペルー、コロンビア、ブラジルのアンデス山系の高地であり、ナスタチウム(Masturtium)という英名は、オランダガラシ(Nasturtium officinale)のことであるが、両者の辛さが類似することからこの名がある。 Nastachium (Tropaeolum majus) (hereinafter referred to as Nastatium) is a perennial plant grown in flower beds and potted plants as an annual sowing of spring, and its genus is climbing and has a length of 1-2 m, and its leaves resemble lotus leaves. It is like a bowl. Its origin is the highlands of the Andes in Peru, Colombia and Brazil, and the English name “Masturtium” is Dutch Dutch (Nasturtium officinale). .
本発明の抗疲労食品素材が、マカ及び/又はナスタチウムの抽出物又は濃縮抽出物からなる場合、マカ及び/又はナスタチウムの、葉、地下部、種子、芽等のいずれの部位を使用して抗疲労食品素材を製造してもよいが、好ましくは、マカの地下部、ナスタチウムの葉部の抽出物又は濃縮抽出物が使用される。尚、前記地下部は胚軸及び根を含む。抽出前に、予め植物を乾燥、細切、又は粉砕など加工を施した加工物を抽出してもよいし、或いはマカ及び/又はナスタチウムを何ら加工せずそのまま使用して抽出物又は濃縮抽出物を得てもよい。 When the anti-fatigue food material of the present invention comprises an extract or concentrated extract of maca and / or nastathium, it can be used with any part of maca and / or nastathium, such as leaves, underground parts, seeds, and buds. Fatigue food materials may be produced, but preferably, an extract or concentrated extract of a maca underground part or a nastatiium leaf part is used. The underground part includes the hypocotyl and the root. Prior to extraction, a processed product obtained by previously drying, chopping, or crushing the plant may be extracted, or the maca and / or nastathium may be used as is without being processed at all. You may get
本発明に係るマカ及び/又はナスタチウムの抽出物又は濃縮抽出物の製造方法は好ましくは次の通りである。
マカ及び/又はナスタチウムの乾燥物、細切物、或いは粉砕物などの加工物、或いは加工していないそのままのマカ及び/又はナスタチウムを低温加熱抽出する。この際に使用される抽出溶媒として、水、エタノール、或いは水とエタノールの混合溶液が挙げられるが、好ましくは、水とエタノールの混合溶液である。さらに好ましくは水:エタノールが重量比率1:6〜8で混合されてなるエタノール水溶液である。特にマカ及び/又はナスタチウムのエタノールと水の混合溶液による抽出物を使用すると、ベンジルグルコシノレートが優先的に抽出されるため工業的利便性に優れるとともに、得られた抗疲労食品素材は高い抗疲労効果を奏することとなる。
さらに、ろ過して抽出液を得た後、この抽出液を濃縮する。濃縮物を液状のまま使用してその濃縮抽出物を本発明の抗疲労食品素材としてもよい。或いは、濃縮の後、凍結乾燥又は粉砕することにより得られる抽出物を本発明の抗疲労食品素材としてもよい。
The method for producing an extract or concentrated extract of maca and / or nastathium according to the present invention is preferably as follows.
Macada and / or nastatium dried products, shredded products, or processed products such as pulverized products, or unprocessed maca and / or nastatium are extracted by heating at low temperature. Examples of the extraction solvent used at this time include water, ethanol, or a mixed solution of water and ethanol, and a mixed solution of water and ethanol is preferable. More preferred is an aqueous ethanol solution in which water: ethanol is mixed at a weight ratio of 1: 6-8. In particular, when an extract of a mixed solution of maca and / or nastathium in ethanol and water is used, benzylglucosinolate is preferentially extracted, so that it is excellent in industrial convenience and the obtained anti-fatigue food material has a high resistance. There will be a fatigue effect.
Furthermore, after filtering and obtaining an extract, this extract is concentrated. The concentrate may be used in the liquid state and the concentrated extract may be used as the anti-fatigue food material of the present invention. Alternatively, an extract obtained by freeze-drying or pulverizing after concentration may be used as the anti-fatigue food material of the present invention.
他の実施形態として、本発明の抗疲労食品素材は、マカ及び/又はナスタチウムの葉、地下部、種子、芽等のいずれか一種以上の部位からなり、少なくとも上式(化4)で示されるベンジルグルコシノレートを含む。尚、前記地下部は胚軸及び根を含む。 As another embodiment, the anti-fatigue food material of the present invention is composed of one or more parts such as maca and / or nastathium leaves, underground parts, seeds, buds, etc., and is represented by at least the above formula (Formula 4). Contains benzyl glucosinolate. The underground part includes the hypocotyl and the root.
前記実施形態において、マカは、葉、地下部、種子、芽等のいずれの部位を使用してもよいが、好ましくは地下部が使用される。ナスタチウムは、葉、地下部、種子、芽等のいずれの部位を使用してもよいが、好ましくは葉が使用される。本発明の抗疲労食品素材とするために、マカ及び/又はナスタチウムを加工せずにそのまま使用してもよいし、乾燥、細切、或いは粉砕などした加工物で抗疲労食品素材を製造してもよい。 In the said embodiment, although maca may use any site | parts, such as a leaf, an underground part, a seed, and a bud, Preferably an underground part is used. Nastatin may be used in any part such as leaves, underground parts, seeds, buds, etc., but preferably leaves are used. In order to make the anti-fatigue food material of the present invention, maca and / or nastathium may be used as they are without being processed, or the anti-fatigue food material is manufactured with a dried, shredded, or pulverized processed product. Also good.
その他の実施形態として、本発明の抗疲労食品素材は、少なくともベンジルグルコシノレートを含有するパパイア(Carica.papaya L.)の抽出物又は濃縮抽出物を使用して製造されてもよい。パパイアの葉、地下部、種子、芽等のいずれの部位を使用してもよいが、好ましくはパパイアの種子が使用される。尚、前記地下部は胚軸及び根を含む。
抽出方法としては、この種子の乾燥物、細切物、或いは粉砕物などの加工物、或いは加工していないそのままのパパイアを低温加熱抽出する。この際に使用される抽出溶媒として、水及び/又はエタノールが挙げられる。ろ過して抽出液を得た後、この抽出液を濃縮する。濃縮物を液状のまま、即ち濃縮抽出物を使用して本発明の抗疲労食品素材としてもよい。或いは、濃縮の後、凍結乾燥又は粉砕することにより抽出物を得て、本発明の抗疲労食品素材としてもよい。
As another embodiment, the anti-fatigue food material of the present invention may be manufactured using an extract or concentrated extract of papaya (Carica.papaya L.) containing at least benzylglucosinolate. Any part of papaya leaves, basement, seeds, buds, etc. may be used, but preferably papaya seeds are used. The underground part includes the hypocotyl and the root.
As an extraction method, a processed product such as a dried product, a shredded product, or a pulverized product of this seed, or an unprocessed papaya is extracted by heating at a low temperature. Examples of the extraction solvent used at this time include water and / or ethanol. After filtration to obtain an extract, the extract is concentrated. The concentrate may remain in a liquid state, that is, the concentrated extract may be used as the anti-fatigue food material of the present invention. Alternatively, the concentrate may be freeze-dried or pulverized to obtain an extract, which may be used as the anti-fatigue food material of the present invention.
他の実施形態として、本発明の抗疲労食品素材は、前記パパイアをそのまま使用してもよい。使用される部位としては、パパイアの葉、胚軸及び根を含む地下部、種子、芽等のいずれの部位を使用してもよい。好ましくはパパイアの種子が使用される。 As another embodiment, the anti-fatigue food material of the present invention may use the papaya as it is. As a site | part used, you may use any site | parts, such as a papaya leaf, the hypodermis part containing a hypocotyl, and a root, a seed, a bud. Papaya seeds are preferably used.
その他の実施形態として、本発明の食品素材は、少なくとも上式(化4)で示されるベンジルグルコシノレートを含むワサビノキ(Moringa Oleifera)又はMoringa stenopetalaの抽出物又は濃縮抽出物を使用して製造されてもよい。ワサビノキ又はMoringa stenopetalaの葉、胚軸及び根を含む地下部、種子、芽、根等のいずれの部位を使用してもよいが、好ましくはワサビノキ又はMoringa stenopetalaの葉及び根が使用され、例えば、次のような方法により濃縮抽出物及び/又は抽出物を得ることができる。前記部位の乾燥物、細切物、或いは粉砕物などの加工物、或いは加工していないそのままのパパイアを低温加熱抽出する。この際に使用される抽出溶媒として、水及び/又はエタノールが挙げられる。さらにろ過して抽出液を得た後、この抽出液を濃縮する。濃縮物を液状のまま、即ち濃縮抽出物を使用して本発明の抗疲労食品素材としてもよい。或いは、濃縮の後、凍結乾燥又は粉砕することにより抽出物を得て、本発明の抗疲労食品素材としてもよい。 In another embodiment, the food material of the present invention is manufactured using an extract or concentrated extract of Wasinga (Moringa Oleifera) or Moringa stenopeneta containing at least benzylglucosinolate represented by the above formula (Formula 4). May be. Wasabikin or Moringa stenopetala leaves, hypocotyls including hypocotyls and roots, seeds, buds, roots, etc. may be used, but preferably horseradish or Moringa stenopetala leaves and roots are used, for example, A concentrated extract and / or extract can be obtained by the following method. A processed product such as a dried product, a shredded product, a pulverized product, or an unprocessed papaya is extracted by heating at a low temperature. Examples of the extraction solvent used at this time include water and / or ethanol. Further, after filtering to obtain an extract, the extract is concentrated. The concentrate may remain in a liquid state, that is, the concentrated extract may be used as the anti-fatigue food material of the present invention. Alternatively, the concentrate may be freeze-dried or pulverized to obtain an extract, which may be used as the anti-fatigue food material of the present invention.
他の実施形態として、本発明の抗疲労食品素材は、ワサビノキ又はMoringa stenopetalaをそのまま使用してもよい。使用される部位としては、ワサビノキ又はMoringa stenopetalaの葉、胚軸及び根を含む地下部、種子、芽、根等のいずれの部位を使用してもよい。好ましくはワサビノキ又はMoringa stenopetalaの葉及び根が使用される。 As another embodiment, the anti-fatigue food material of the present invention may use wasabi or Moringa stenopetala as it is. As a site | part used, you may use any site | parts, such as a horseradish or Moringa stenopetala leaf, a hypodermis part containing a hypocotyl and a root, a seed, a bud, a root. Preferably the leaves and roots of horseradish or Moringa stenopetala are used.
本発明の抗疲労食品は、前記抗疲労食品素材を含有してなる。
本発明の抗疲労食品には、前記抗疲労食品素材が、ベンジルグルコシノレート含量が0.00001〜10重量%となるように含有される。より詳細には、本発明の抗疲労食品が、健康食品等の錠剤形状とされる場合は、抗疲労食品素材は、ベンジルグルコシノレート含量が0.1〜3重量%となるように含有される。例えば、ペットボトル飲料等の飲料水とされる場合は0.00001〜0.0001重量%となるように含有される。例えば、菓子類や加工食品等の嗜好食品おいては、抗疲労食品素材が、ベンジルグルコシノレート含量が0.00001〜10重量%となるように含有される。この理由は、このような嗜好食品においてベンジルグルコシノレートが10重量%を超えると、舌触り、味覚等に劣るため好ましくない。また、0.00001重量%未満の場合は、抗疲労や抗酸化の効果が期待できないためいずれの場合も好ましくないからである。
The anti-fatigue food of the present invention contains the anti-fatigue food material.
The anti-fatigue food of the present invention contains the anti-fatigue food material so that the benzylglucosinolate content is 0.00001 to 10% by weight. More specifically, when the anti-fatigue food of the present invention is in the form of a tablet such as a health food, the anti-fatigue food material is contained so that the benzylglucosinolate content is 0.1 to 3% by weight. For example, when it is set as drinking water, such as a PET bottle drink, it is contained so that it may become 0.00001-0.0001 weight%. For example, in taste foods such as confectionery and processed foods, the anti-fatigue food material is contained so that the benzylglucosinolate content is 0.00001 to 10% by weight. For this reason, if the benzyl glucosinolate exceeds 10% by weight in such a preferred food, it is not preferable because it is inferior to the touch and taste. In addition, if it is less than 0.00001% by weight, the anti-fatigue and anti-oxidation effects cannot be expected.
本発明の抗疲労食品には、好ましくは、前記抗疲労食品素材の他に、ビタミンCが含有される。このビタミンCを含むことにより、本発明の抗疲労食品は酸化ストレスから産生される活性酸素を抑える効果を奏するとともに、相乗的に優れた抗疲労効果を示す。 The anti-fatigue food of the present invention preferably contains vitamin C in addition to the anti-fatigue food material. By containing this vitamin C, the anti-fatigue food of the present invention has an effect of suppressing active oxygen produced from oxidative stress and synergistically exhibits an excellent anti-fatigue effect.
本発明の抗疲労食品には、食品の種類に応じて慣用の添加剤を使用することができる。
添加剤としては、例えば、賦形剤、pH調整剤、清涼化剤、懸濁化剤、消泡剤、粘稠剤、溶解補助剤、崩壊剤、結合剤、滑沢剤、コーティング剤、着色剤、矯味矯臭剤、界面活性剤又は可塑剤などが挙げられる。
In the anti-fatigue food of the present invention, conventional additives can be used depending on the type of food.
Examples of additives include excipients, pH adjusting agents, cooling agents, suspending agents, antifoaming agents, thickening agents, solubilizing agents, disintegrating agents, binders, lubricants, coating agents, and coloring agents. Agents, flavoring agents, surfactants or plasticizers.
前記賦形剤としては、例えば、D−ソルビトール、D−マンニトール或いはキシリトールなどの糖アルコール、ブドウ糖、白糖、乳糖或いは果糖などの糖類、結晶セルロース、カルメロースナトリウム、りん酸水素カルシウム、コムギデンプン、コメデンプン、トウモロコシデンプン、バレイショデンプン、デキストリン、βーシクロデキストリン、軽質無水ケイ酸、酸化チタン、又はメタケイ酸アルミン酸マグネシウムなどが挙げられる。 Examples of the excipient include sugar alcohols such as D-sorbitol, D-mannitol and xylitol, sugars such as glucose, sucrose, lactose and fructose, crystalline cellulose, carmellose sodium, calcium hydrogen phosphate, wheat starch, rice Examples thereof include starch, corn starch, potato starch, dextrin, β-cyclodextrin, light anhydrous silicic acid, titanium oxide, or magnesium aluminate metasilicate.
前記pH調整剤としては、例えばクエン酸、リンゴ酸、リン酸水素ナトリウム又はリン酸二カリウムなどが挙げられる。前記清涼化剤としては、例えばl−メントール又はハッカ水などが挙げられる。前記懸濁化剤としては、例えば、カオリン、カルメロースナトリウム、キサンタンガム、メチルセルロース又はトラガントなどが挙げられる。前記消泡剤としては、例えばジメチルポリシロキサン又はシリコン消泡剤などが挙げられる。 Examples of the pH adjuster include citric acid, malic acid, sodium hydrogen phosphate, and dipotassium phosphate. Examples of the refreshing agent include l-menthol or mint water. Examples of the suspending agent include kaolin, carmellose sodium, xanthan gum, methylcellulose, and tragacanth. Examples of the antifoaming agent include dimethylpolysiloxane or silicon antifoaming agent.
前記粘稠剤としては、例えばキサンタンガム、トラガント、メチルセルロース又はデキストリンなどが挙げられる。前記溶解補助剤としては、例えばエタノール、ショ糖脂肪酸エステル又はマクロゴールなどが挙げられる。前記崩壊剤としては、例えば低置換度ヒドロキシプロピルセルロース、カルボキシメチルセルロースカルシウム、クロスカルメロースナトリウム、ヒドロキシプロピルスターチ又は部分アルファー化デンプンなどが挙げられる。前記結合剤としては、例えばメチルセルロース、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ポリビニールピロリドン、ゼラチン、アラビアゴム、エチルセルロース、ポリビニルアルコール、プルラン、アルファー化デンプン、カンテン、トラガント、アルギン酸ナトリウム又はアルギン酸プロピレングリコールエステルなどが挙げられる。 Examples of the thickener include xanthan gum, tragacanth, methylcellulose, and dextrin. Examples of the solubilizer include ethanol, sucrose fatty acid ester, and macrogol. Examples of the disintegrant include low-substituted hydroxypropylcellulose, carboxymethylcellulose calcium, croscarmellose sodium, hydroxypropyl starch, and partially pregelatinized starch. Examples of the binder include methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, gelatin, gum arabic, ethylcellulose, polyvinyl alcohol, pullulan, pregelatinized starch, agar, tragacanth, sodium alginate or propylene glycol alginate. Can be mentioned.
前記滑沢剤としては、例えばステアリン酸、ステアリン酸マグネシウム、ステアリン酸カルシウム、ステアリン酸ポリオキシル、セタノール、タルク、硬化油、ショ糖脂肪酸エステル、ジメチルポリシロキサン、ミツロウ又はサラシミツロウなどが挙げられる。 Examples of the lubricant include stearic acid, magnesium stearate, calcium stearate, polyoxyl stearate, cetanol, talc, hydrogenated oil, sucrose fatty acid ester, dimethylpolysiloxane, beeswax and beeswax.
本発明の抗疲労食品には、必要に応じて、他の生理活性成分、ミネラル、ビタミン、ホルモン、栄養成分、香料などの添加物を混合することができる。これらの添加物はいずれも一般的に食品に用いられるものが使用できる。 The anti-fatigue food of the present invention can be mixed with other physiologically active ingredients, minerals, vitamins, hormones, nutritional ingredients, flavors, and other additives as necessary. Any of these additives generally used in foods can be used.
本発明の抗疲労食品の形状としては、例えば、ハードカプセル、ソフトカプセルのようなカプセル、錠剤、丸剤、顆粒状などの形状に加工され得る。本発明の抗疲労食品は、例えば健康食品として供給することができる。 The anti-fatigue food of the present invention can be processed into a shape such as a capsule such as a hard capsule or a soft capsule, a tablet, a pill, or a granule. The anti-fatigue food of the present invention can be supplied as a health food, for example.
他の実施形態としては、本発明の抗疲労食品素材を食品に添加して、抗疲労食品を製造してもよい。前記食品としては、例えば、スナック、ビスケット、クッキー、チョコレート等の菓子類、ジュース、お茶等の飲料水等が挙げられる。 As another embodiment, the anti-fatigue food material of the present invention may be added to food to produce an anti-fatigue food. Examples of the food include confectionery such as snacks, biscuits, cookies, and chocolate, and drinking water such as juice and tea.
尚、本発明の抗疲労食品は、ベンジルグルコシノレートの1日摂取量が1〜5mgとなるように摂取することが好ましい。1日摂取量が1mg未満の場合は、十分な抗疲労効果が期待できず、また5mgを超えて摂取してもそれ以上の効果が期待できないと推測されるためいずれの場合も好ましくない。
次に、実施例を挙げて本発明を更に具体的に説明する。
In addition, it is preferable to ingest the anti-fatigue food of this invention so that the daily intake of benzylglucosinolate may be 1-5 mg. When the daily intake is less than 1 mg, a sufficient anti-fatigue effect cannot be expected, and even if the intake exceeds 5 mg, it is estimated that no further effect can be expected.
Next, the present invention will be described more specifically with reference to examples.
本発明の抗疲労食品素材に含まれるベンジルグルコシノレートについて、マウスを使用して抗疲労効果及び抗酸化効果に関する試験を行った。 About the benzyl glucosinolate contained in the anti-fatigue food material of this invention, the test regarding the anti-fatigue effect and the antioxidant effect was done using the mouse | mouth.
(実験方法/使用マウスとその飼育・試験方法)
試験には、BALB/cマウス、メス、8週齢を使用し、(1)コントロール運動負荷群(20匹)(2)コントロール明暗負荷群(19匹)、(3)ベンジルグルコシノレート投与運動負荷群(20匹)、(4)ベンジルグルコシノレート投与明暗負荷群(19匹)とした。尚、(1)〜(4)のBALB/cマウスは全ての予備飼育を行ったものである。
(Experimental method / use mouse and its breeding / testing method)
For the test, BALB / c mice, females, 8 weeks of age were used. (1) Control exercise load group (20 mice) (2) Control light / dark load group (19 mice), (3) Exercise with benzylglucosinolate Load group (20 animals), (4) benzylglucosinolate administration light / dark load group (19 animals). The BALB / c mice (1) to (4) were all preliminarily reared.
試験方法に関して、図1を参照する。図1中[投与開始]から[投与終了]の間の12週間、ベンジルグルコシノレート投与群((3)及び(4))に対し、ベンジルグルコシノレート(Benzyl glucosinolate[Lot. 07300-102,CHROMADEC INC])を1回0.03mg/kgの割合で1日1回、経口投与を行った。コントロール群((1)及び(2))については同量の蒸留水を経口投与により同じ期間行った。 Refer to FIG. 1 for the test method. In FIG. 1, benzylglucosinolate (Benzyl glucosinolate [Lot. 07300-102, 12) was administered to the benzylglucosinolate administration group ((3) and (4)) for 12 weeks between [administration start] and [administration end]. CHROMADEC INC]) was orally administered once a day at a rate of 0.03 mg / kg. For the control group ((1) and (2)), the same amount of distilled water was orally administered for the same period.
[投与開始]から4週間後に負荷を開始する。図1中[負荷開始]において、運動負荷群((1)と(3))には、動物用トレッドミル(品名:スモールランニングボール、製造元:MR-24 株式会社 マルカン)を用い、5日/週、1日20分の運動を行った。明暗負荷群((2)と(4))に対しては、ケージから30cmの位置から200W白熱灯(品名:クリップランプ、製造元:LC−200 株式会社高儀)で45分間、毎日照明をあてた。
図1中[負荷終了]において、運動負荷及び明暗負荷を終了した。尚、[負荷開始]から[負荷終了]まで4週間である。
The loading starts 4 weeks after [start of administration]. In [Load start] in FIG. 1, an animal treadmill (product name: small running ball, manufacturer: MR-24 Marcan Co., Ltd.) is used for the exercise load group ((1) and (3)) for 5 days / I exercised 20 minutes a day a week. The light and dark load groups ((2) and (4)) were illuminated daily for 45 minutes with a 200 W incandescent lamp (product name: clip lamp, manufacturer: LC-200, Takagi) from a
In FIG. 1, at the end of load, the exercise load and the light / dark load were completed. It is 4 weeks from [Load start] to [Load end].
[負荷終了]から4週間後に、投与(ベンジルグルコシノレート投与群((3)及び(4))に対しベンジルグルコシノレート、コントロール群((1)及び(2))に対し蒸留水)を終了した。尚、[負荷終了]から[投与終了]は4週間である。 Four weeks after [end of loading], administration (benzyl glucosinolate for benzyl glucosinolate administration group ((3) and (4)), distilled water for control group ((1) and (2))) finished. In addition, [end of loading] to [end of administration] is 4 weeks.
(採血方法)
[負荷開始]、[負荷終了]、[投与終了]時に、各群より血球測定及び眼底採血、心臓採血をし、得た血液から血清を採取し冷凍保存した。全採血終了後、各血清について抗酸化濃度及びEIA kitを用いて脳内ホルモンの測定を行った。
(体重測定)
[投与開始]から[投与終了]までの間、1週間ごとにマウスの体重測定を行った。
(Blood collection method)
At the start of loading, at the end of loading, and at the end of administration, blood group measurement, fundus blood collection, and heart blood collection were performed from each group, and serum was collected from the obtained blood and stored frozen. After completion of all blood collections, brain hormones were measured for each serum using antioxidant concentration and EIA kit.
(Weight measurement)
Mice were weighed every week from the start of administration to the end of administration.
(ルミノール反応によるAAPH測定方法と結果)
マウス群((1)〜(4))から得られた血清を0.1MPBS(pH7)にて100倍に希釈し、AAPH試薬を加えたものをサンプルとした。ルミネッセンスリーダーにサンプルを挿入し、37℃に10分加温時点でルミノール試薬を注入し、発光量を測定した。発光量が少ないほどラジカル消去(Radical scavenging)能力が高い。すなわち発光量が少ないほど抗酸化濃度が高いと言える。結果を図2に示す。
(AAPH measurement method and result by luminol reaction)
Serum obtained from a group of mice ((1) to (4)) was diluted 100-fold with 0.1 M PBS (pH 7) and added with AAPH reagent as a sample. A sample was inserted into a luminescence reader, and a luminol reagent was injected at 37 ° C. for 10 minutes, and the amount of luminescence was measured. The smaller the amount of luminescence, the higher the radical scavenging ability. That is, it can be said that the smaller the amount of luminescence, the higher the antioxidant concentration. The results are shown in FIG.
図2が示すとおり、コントロール群と比較してベンジルグルコシノレート投与群にAAPH発光の減少が見られた。即ち、ベンジルグルコシノレート投与群において、抗酸化効果を示した。従って、本発明に係るベンジルグルコシノレートは抗酸化効果を奏するから、抗酸化食品素材或いは抗酸化食品としても好適に使用できる。 As shown in FIG. 2, a decrease in AAPH luminescence was observed in the benzylglucosinolate administration group compared to the control group. That is, the antioxidant effect was shown in the benzyl glucosinolate administration group. Therefore, since the benzyl glucosinolate according to the present invention exhibits an antioxidant effect, it can be suitably used as an antioxidant food material or an antioxidant food.
(マウスの体重測定結果)
図3を参照する。図3が示すとおり、コントロール群と比較してベンジルグルコシノレート投与群では負荷時に体重の減少が少なかった。即ち、ベンジルグルコシノレート投与によって、疲労負荷による体重減少が抑えられた。
(Mouse weight measurement results)
Please refer to FIG. As shown in FIG. 3, the benzylglucosinolate-administered group showed less weight loss during loading compared to the control group. That is, weight loss due to fatigue load was suppressed by administration of benzylglucosinolate.
(免疫増強効果に関する試験結果)
図4乃至6は、(1)〜(4)マウス群の血清中の白血球(図4)及びリンパ球(図5)、顆粒球(図6)の数を示す。これらの図が示す通り、明暗負荷マウスにおいて白血球及びリンパ球の数、顆粒球の数の減少抑制が見られた。運動負荷マウスにおいては白血球及びリンパ球数の減少抑制、顆粒球数の上昇が見られた。このことから、ベンジルグルコシノレートを投与することにより、運動及び明暗負荷による免疫機能の低下が改善されたことがわかる。
(Test results on immune enhancement effect)
FIGS. 4 to 6 show the numbers of leukocytes (FIG. 4), lymphocytes (FIG. 5), and granulocytes (FIG. 6) in the serum of (1) to (4) mouse groups. As shown in these figures, suppression of decrease in the number of leukocytes and lymphocytes and granulocytes was observed in the light and dark loaded mice. In the exercised mice, the decrease in the number of leukocytes and lymphocytes and the increase in the number of granulocytes were observed. From this, it can be seen that administration of benzylglucosinolate improved the decrease in immune function due to exercise and light and dark load.
(EIA kitを用いた脳内ホルモンの測定結果)
図7は、(1)〜(4)マウス群の血清中のセロトニン濃度を測定した結果である。図7が示すとおり、ベンジルグルコシノレート投与群において、負荷終了時にセロトニン濃度の低下抑制が見られた。従って、ベンジルグルコシノレート投与によるセロトニン濃度の低下抑制により抑うつ感が軽減されたと考えられる。
図8は、(1)〜(4)マウス群の血清中のドーパミン濃度を測定した結果である。ベンジルグルコシノレート投与群において、負荷終了時にドーパミン濃度の上昇が見られた。従って、ベンジルグルコシノレート投与によるドーパミン濃度上昇により、疲労感が低減されたと考えられる。
(Measurement result of hormones in the brain using EIA kit)
FIG. 7 shows the results of measuring the serotonin concentration in the serum of (1) to (4) mouse groups. As shown in FIG. 7, in the benzylglucosinolate administration group, suppression of the decrease in serotonin concentration was observed at the end of the load. Therefore, it is considered that depression was reduced by suppressing the decrease in serotonin concentration by administration of benzyl glucosinolate.
FIG. 8 shows the results of measuring the dopamine concentration in the serum of (1) to (4) mouse groups. In the benzylglucosinolate administration group, an increase in dopamine concentration was observed at the end of loading. Therefore, it is thought that the feeling of fatigue was reduced by the increase in dopamine concentration by administration of benzylglucosinolate.
以上の試験結果から、ベンジルグルコシノレートは、抗酸化効果によりストレスを軽減するとともに、疲労マウスにおいて、脳内ホルモン分泌低下を抑制することが確認できた。 From the above test results, it was confirmed that benzylglucosinolate relieves stress by an antioxidant effect and suppresses a decrease in brain hormone secretion in fatigue mice.
さらに、本発明の抗疲労食品素材に含まれるベンジルグルコシノレートについて、マウスを使用して持久力向上効果及び抗疲労効果に関する試験を行った。 Furthermore, about the benzyl glucosinolate contained in the anti-fatigue food material of this invention, the test regarding the endurance improvement effect and the anti-fatigue effect was done using the mouse | mouth.
(ベンジルグルコシノレート投与による遊泳運動への影響)
Std: ddYマウス、4週齢オスを7日間予備飼育した後、(A)コントロール、(B)マカ抽出物30mg/kg、(C)ベンジルグルコシノレート0.03mg/kg、(D)ベンジルグルコシノレート0.015mg/kg、(E)ベンジルグルコシノレート0.0075mg/kgに群分けし投与を行った。(2回目n=10)
尚、(B)マカ抽出物は、マカの地下部を含水エタノールで抽出し、フリーズドライ加工を経て粉末化したものである。
(Influence on swimming exercise by administration of benzylglucosinolate)
Std: ddY mice, 4 weeks old males were preliminarily raised for 7 days, then (A) control, (B)
In addition, (B) Maca extract is obtained by extracting the underground part of maca with hydrous ethanol and pulverizing it by freeze-drying.
(強制遊泳実験)
マウスの尾部に体重の10%の重りを負荷し、マウスが水面下に頭部を完全に5秒間沈めるまでの時間を測定し、遊泳持続時間を持久時間とし判定を行った。遊泳運動は1週間毎に実施した。結果を図9に示す。図9において、横軸は時間(週)、縦軸は時間(分)を示す。
(Forced swimming experiment)
A weight of 10% of the body weight was applied to the tail of the mouse, the time until the mouse completely submerges the head under the water for 5 seconds was measured, and the swimming duration was determined as the endurance time. Swimming exercise was carried out every week. The results are shown in FIG. In FIG. 9, the horizontal axis represents time (weeks) and the vertical axis represents time (minutes).
(一定時間の強制遊泳実験)
マウスに5%の重りを負荷し、15分間の遊泳運動を行わせ、その際、遊泳運動前・遊泳運動中(5、10、15分)・遊泳運動後(10、30、60分)に尾部より採血し、血液中グルコース(図10)、血液中乳酸(図11)、遊離脂肪酸(図12)の測定を行った。尚、図12及び13のグラフの横軸は時間(分)である。さらに、図13には、遊泳運動前後の肝臓グリコーゲン量の変化、図14には5週間投与後の脂肪組織重量の変化を示した。
(Forced swimming experiment for a certain time)
The mouse is loaded with a 5% weight and allowed to perform a 15 minute swimming exercise before, during the swimming exercise (5, 10, 15 minutes) or after the swimming exercise (10, 30, 60 minutes). Blood was collected from the tail, and blood glucose (FIG. 10), blood lactic acid (FIG. 11), and free fatty acid (FIG. 12) were measured. The horizontal axis of the graphs of FIGS. 12 and 13 is time (minutes). Further, FIG. 13 shows changes in the amount of liver glycogen before and after swimming exercise, and FIG. 14 shows changes in the weight of adipose tissue after administration for 5 weeks.
図9乃至14に示されるとおり、本発明に係るマカ抽出物、又はベンジルグルコシノレートを投与したマウスにおいて、マウスの遊泳時間の延長が認められ、遊泳運動による血液中乳酸の上昇を抑制するとともに、運動時に、血液中遊離脂肪酸の上昇が認められた。さらに、ベンジルグルコシノレートは、マウスの脂肪組織重量を減少させ、運動時の組織中グリコーゲンの減少を抑えた。以上のことより、本発明の食品素材は、抗疲労及び抗酸化効果を付与するばかりか、運動時に糖代謝よりも脂質代謝を促進し、本発明の食品素材は、運動時のエネルギー源として使用されうることが分かった。
即ち、本発明の食品素材は持久力向上及び抗疲労効果を有するから、抗疲労食品素材として好適に使用できる。
As shown in FIGS. 9 to 14, in the mice administered with the maca extract or benzylglucosinolate according to the present invention, an increase in the swimming time of the mice was observed, and an increase in blood lactic acid due to swimming exercise was suppressed. During exercise, an increase in free fatty acids in the blood was observed. Furthermore, benzylglucosinolate reduced the fat tissue weight of mice and suppressed the decrease of tissue glycogen during exercise. From the above, the food material of the present invention not only provides anti-fatigue and antioxidant effects, but also promotes lipid metabolism rather than glucose metabolism during exercise, and the food material of the present invention is used as an energy source during exercise It turns out that it can be done.
That is, since the food material of the present invention has endurance improvement and anti-fatigue effects, it can be suitably used as an anti-fatigue food material.
(マカ抽出物の血液中ヘモグロビン濃度への影響に関する試験)
4週齢のマウス(n=10)を用い、コントロール群と2つの投与群(マカ抽出物6mg/kg、30mg/kg)の3群に分け4週間の経口投与を行った。尚、このマカ抽出物は、マカの地下部を含水エタノールで抽出し、フリーズドライ加工後粉末化としたものである。各群について、4週間投与後の血液中ヘモグロビン濃度の測定を行った。結果を図15に示す。
(Test on the effect of maca extract on blood hemoglobin concentration)
Four-week-old mice (n = 10) were used and divided into three groups, a control group and two administration groups (Maca extract 6 mg / kg, 30 mg / kg), and oral administration was performed for 4 weeks. This maca extract is obtained by extracting the underground part of maca with hydrous ethanol and pulverizing it after freeze-drying. Each group was measured for blood hemoglobin concentration after 4 weeks of administration. The results are shown in FIG.
図15が示すとおり、マカ抽出物が投与されたマウスにおいて、血液中ヘモグロビン濃度の上昇が認められた。これにより、血液中ヘモグロビン濃度の増加によって組織への酸素供給量が増加するから、本発明に係るマカ抽出物は運動時のエネルギー源となり得ることが分かった。 As shown in FIG. 15, an increase in blood hemoglobin concentration was observed in mice administered with maca extract. As a result, it was found that the maca extract according to the present invention can serve as an energy source during exercise since the oxygen supply amount to the tissue increases due to an increase in blood hemoglobin concentration.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007082940A JP2008237117A (en) | 2007-03-27 | 2007-03-27 | Anti-fatigue food raw material and anti-fatigue food |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007082940A JP2008237117A (en) | 2007-03-27 | 2007-03-27 | Anti-fatigue food raw material and anti-fatigue food |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2008237117A true JP2008237117A (en) | 2008-10-09 |
Family
ID=39909203
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007082940A Pending JP2008237117A (en) | 2007-03-27 | 2007-03-27 | Anti-fatigue food raw material and anti-fatigue food |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2008237117A (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014208608A (en) * | 2013-03-22 | 2014-11-06 | ライオン株式会社 | Glucose metabolism improving agent |
JP2015199713A (en) * | 2014-03-31 | 2015-11-12 | 日本メナード化粧品株式会社 | External and internal preparation for skin containing nasturtium extract irradiated with light having specific wavelength band to cultivate |
KR20160058208A (en) * | 2014-10-29 | 2016-05-25 | 한국식품연구원 | Composition for inhibiting toxicity of bisphenol A comprising glucosinolate |
CN106581017A (en) * | 2016-12-20 | 2017-04-26 | 海南医学院 | Preparation method and application of papaya seed benzyl glucosinolate extract |
WO2017073473A1 (en) * | 2015-10-28 | 2017-05-04 | 太陽化学株式会社 | Moringa extract |
KR101748941B1 (en) | 2015-07-24 | 2017-07-03 | 농업회사법인 주식회사 수신오도 | Method for producing a Moringa kimchi seasoning |
WO2020116092A1 (en) | 2018-12-07 | 2020-06-11 | 太陽化学株式会社 | Composition containing extract and/or ground product of moringa |
JP2020150918A (en) * | 2019-03-22 | 2020-09-24 | 阿万 恵理 | Moringa fermented food |
JP2021185145A (en) * | 2016-10-24 | 2021-12-09 | ジェイディーエス・セラピューティクス、エルエルシー | Maca composition and usage |
-
2007
- 2007-03-27 JP JP2007082940A patent/JP2008237117A/en active Pending
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014208608A (en) * | 2013-03-22 | 2014-11-06 | ライオン株式会社 | Glucose metabolism improving agent |
JP2015199713A (en) * | 2014-03-31 | 2015-11-12 | 日本メナード化粧品株式会社 | External and internal preparation for skin containing nasturtium extract irradiated with light having specific wavelength band to cultivate |
KR20160058208A (en) * | 2014-10-29 | 2016-05-25 | 한국식품연구원 | Composition for inhibiting toxicity of bisphenol A comprising glucosinolate |
KR101706649B1 (en) | 2014-10-29 | 2017-02-14 | 한국식품연구원 | Composition for inhibiting toxicity of bisphenol A comprising glucosinolate |
KR101748941B1 (en) | 2015-07-24 | 2017-07-03 | 농업회사법인 주식회사 수신오도 | Method for producing a Moringa kimchi seasoning |
WO2017073473A1 (en) * | 2015-10-28 | 2017-05-04 | 太陽化学株式会社 | Moringa extract |
JP6200122B1 (en) * | 2015-10-28 | 2017-09-20 | 太陽化学株式会社 | Moringa extract |
JP2017217006A (en) * | 2015-10-28 | 2017-12-14 | 太陽化学株式会社 | Moringa extract |
US10441618B2 (en) | 2015-10-28 | 2019-10-15 | Taiyo Kagaku Co., Ltd. | Moringa extract |
JP2021185145A (en) * | 2016-10-24 | 2021-12-09 | ジェイディーエス・セラピューティクス、エルエルシー | Maca composition and usage |
US12201661B2 (en) | 2016-10-24 | 2025-01-21 | Bonafide Health, Llc | Maca compositions and methods of use |
US11752186B2 (en) | 2016-10-24 | 2023-09-12 | Jds Therapeutics, Llc | Maca compositions and methods of use |
JP7177534B2 (en) | 2016-10-24 | 2022-11-24 | ジェイディーエス・セラピューティクス、エルエルシー | Maca Compositions and Methods of Use |
CN106581017A (en) * | 2016-12-20 | 2017-04-26 | 海南医学院 | Preparation method and application of papaya seed benzyl glucosinolate extract |
EP3847896A4 (en) * | 2018-12-07 | 2022-07-20 | Taiyo Kagaku Co., Ltd. | Composition containing extract and/or ground product of moringa |
US10869829B1 (en) | 2018-12-07 | 2020-12-22 | Taiyo Kagaku Co., Ltd. | Composition containing moringa extract and/or pulverized product |
WO2020116092A1 (en) | 2018-12-07 | 2020-06-11 | 太陽化学株式会社 | Composition containing extract and/or ground product of moringa |
JP7282557B2 (en) | 2019-03-22 | 2023-05-29 | 阿万 恵理 | moringa fermented food |
JP2020150918A (en) * | 2019-03-22 | 2020-09-24 | 阿万 恵理 | Moringa fermented food |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US12121557B2 (en) | Medicinal composition of amaranth extract origin having enriched nitrate content and a method of preparing the same | |
JP2008237117A (en) | Anti-fatigue food raw material and anti-fatigue food | |
JP6360972B2 (en) | Composition for preventing or ameliorating non-alcoholic fatty liver disease comprising white pea extract as an active ingredient | |
JP2004075638A (en) | Functional material with blood sugar rise suppression and blood pressure rise suppression | |
KR20200032772A (en) | Beverage composition for treating hangover comprising black ginseng extact | |
JP3768795B2 (en) | Xanthine oxidase inhibitor | |
JP6446162B1 (en) | Hangover composition | |
JP6773361B2 (en) | Mood condition improver | |
KR101507427B1 (en) | Pharmaceutical composition and healthy food for alleviating disorders caused by the andropause | |
JP2002193826A (en) | Tonic and tonic composition | |
KR101045279B1 (en) | Composition of functional food having anti-obesity effect | |
KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
JP2009184992A (en) | Fructose absorption inhibitor, composition, food, pharmaceutical preparation, and animal feed | |
KR20210050034A (en) | A composition for improving, preventing and treating of diabetes mellitus | |
KR20180006612A (en) | Compositions for preventing or treating diabetes mellitus comprising extract of Aster koraiensis or fraction thereof | |
JP4464082B2 (en) | Muscle cell sugar transport enhancing composition containing mugwort as an active ingredient | |
JP2012131760A (en) | Fatty acid absorption inhibitor | |
JP2006016340A (en) | Blood uric acid level reduction agent having extract of punica granatum l. as active ingredient | |
KR102050554B1 (en) | Composition for hangover treatment and manufacturing method for the same | |
KR20170055366A (en) | A composition for preventing or treating obesity comprising taraxacum coreanum root extract | |
JP4714438B2 (en) | Anti-fatigue agent and food and drink containing the same | |
JP6096439B2 (en) | Growth hormone secretagogue | |
WO2021112263A1 (en) | Adiponectin production promoter | |
JP2022168204A (en) | oral composition | |
JP2009268452A (en) | Anti-obesity functional food material and anti-obesity food |